LOS ANGELES — The clock is ticking for Immutep Limited investors. A July 6, 2026 deadline looms for anyone who bought the company’s securities between March 24, 2025 and March 12, 2026. They can still join a class action lawsuit.
The Schall Law Firm is leading the charge. But the real story here is what the company allegedly knew — and when it knew it.
The lawsuit centers on a single trial: TACTI-004. This was the study of eftilagimod alfa, Immutep’s experimental cancer drug. According to the complaint, the company told the market it was making “strong operational progress” in a Form-K filed with the SEC on January 30, 2026.
That filing sits right in the middle of the class period. Here is the allegation: Immutep knew the TACTI-004 trial would fail to meet its primary efficacy endpoints.
The company knew that in January 2026. But it told investors everything was fine. That is the core of the securities fraud claim — violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Take a close look at the numbers. The class period runs from March 24, 2025 to March 12, 2026. That is nearly a full year.
During that entire stretch, Immutep was allegedly concealing the trial’s true status. When the truth finally came out — sometime around March 12, 2026 — investors who bought in during that window took a hit.
The Schall Law Firm is a national shareholder rights litigation firm. They handle these cases regularly. Their Los Angeles office at 2049 Century Park East is fielding calls at 310-301-3335.
They are offering free consultations to discuss investor rights. One thing to understand: the class is not yet certified.
That is a legal step that has not happened. Until it does, no investor is officially represented by an attorney. Anyone who does nothing becomes an absent class member by default.
That means they get whatever the court decides for the group — no individual say. This is not a small firm chasing a fringe case. Immutep is a publicly traded company.
The SEC filing from January 30, 2026 is a public document. The company chose those words — “strong operational progress” — and put them in an official filing.
If the allegations hold, those words were false. The concealment had real consequences. Investors made decisions based on what the company said.
They bought stock. They held stock.
They trusted the public statements. If those statements were knowingly misleading, that is exactly what securities law is designed to catch. For investors who suffered a loss during the class period, the next step is clear.
Contact the Schall Law Firm before July 6. The firm’s website and phone line are open. The consultation is free.
The decision to join or not is individual. But the underlying question remains unanswered.
How did a company that claimed strong operational progress end up with a trial that failed its primary endpoints? The lawsuit alleges the answer is simple: the company knew all along. The court will have to decide if that is true.
Until then, the deadline stands. July 6, 2026.
Investors who act before then get a seat at the table. Everyone else watches from the gallery.
